27474557|t|Xylan-based temperature / pH sensitive hydrogels for drug controlled release
27474557|a|Xylan-based temperature / pH sensitive hydrogels were prepared by the crosslinking copolymerization of xylan with N-isopropylacrylamide (NIPAm) and acrylic acid (AA) using N,Ń-methylenebis-acrylamide (MBA) as a cross-linker and 2,2-dimethoxy-2-phenylacetophenone as a photoinitiator via ultraviolet irradiation. The influence of the NIPAm, AA and MBA amount on properties of xylan-based hydrogels was discussed. The morphology and interactions of hydrogels were characterized by SEM and FTIR. The lower critical solution temperature (LCST) of hydrogels was investigated by DSC. The results indicated that the LCST of hydrogels emerged at around 34°C and increased with increasing the AA content. The drug encapsulation efficiency of as-prepared hydrogels reached to 97.60% and the cumulative release rate of acetylsalicylic acid was 90.12% and 26.35% in the intestinal and gastric fluid, respectively. Xylan-based hydrogels were proved to be biocompatible with NIH3T3 cell by MTT assay and showed the promising application as drug carriers for the intestinal - targeted oral drug delivery.
27474557	0	11	Xylan-based	T109	C0062221
27474557	12	23	temperature	T081	C0039476
27474557	26	28	pH	T081	C0020283
27474557	29	38	sensitive	T169	C0332324
27474557	39	48	hydrogels	T122	C0600484
27474557	53	76	drug controlled release	T122	C1707506
27474557	77	88	Xylan-based	T109	C0062221
27474557	89	100	temperature	T081	C0039476
27474557	103	105	pH	T081	C0020283
27474557	106	115	sensitive	T169	C0332324
27474557	116	125	hydrogels	T122	C0600484
27474557	147	176	crosslinking copolymerization	T044	C1880180
27474557	180	185	xylan	T109	C0062221
27474557	191	212	N-isopropylacrylamide	T109	C0083668
27474557	214	219	NIPAm	T109	C0083668
27474557	225	237	acrylic acid	T109,T122	C1321887
27474557	239	241	AA	T109,T122	C1321887
27474557	249	277	N,Ń-methylenebis-acrylamide	T109,T130	C0067314
27474557	279	282	MBA	T109,T130	C0067314
27474557	289	301	cross-linker	T130	C0034760
27474557	306	340	2,2-dimethoxy-2-phenylacetophenone	T109	C1121773
27474557	346	360	photoinitiator	T109	C0029224
27474557	365	388	ultraviolet irradiation	T070	C0041625
27474557	394	403	influence	T077	C4054723
27474557	411	416	NIPAm	T109	C0083668
27474557	418	420	AA	T109,T122	C1321887
27474557	425	428	MBA	T109,T130	C0067314
27474557	453	464	xylan-based	T109	C0062221
27474557	465	474	hydrogels	T122	C0600484
27474557	494	504	morphology	T080	C0332437
27474557	509	521	interactions	T169	C1704675
27474557	525	534	hydrogels	T122	C0600484
27474557	540	553	characterized	T052	C1880022
27474557	557	560	SEM	T059	C0026020
27474557	565	569	FTIR	T062	C0206055
27474557	575	610	lower critical solution temperature	T081	C0039476
27474557	612	616	LCST	T081	C0039476
27474557	621	630	hydrogels	T122	C0600484
27474557	635	647	investigated	T169	C1292732
27474557	651	654	DSC	T059	C0006780
27474557	660	667	results	T033	C0683954
27474557	687	691	LCST	T081	C0039476
27474557	695	704	hydrogels	T122	C0600484
27474557	762	764	AA	T109,T122	C1321887
27474557	778	782	drug	T121	C0013227
27474557	783	796	encapsulation	T067	C2348438
27474557	797	807	efficiency	T081	C0013682
27474557	823	832	hydrogels	T122	C0600484
27474557	859	869	cumulative	T080	C1511559
27474557	870	877	release	T070	C3850077
27474557	878	882	rate	T081	C1521828
27474557	886	906	acetylsalicylic acid	T109,T121	C0004057
27474557	936	946	intestinal	T023	C0021853
27474557	951	964	gastric fluid	T031	C2828094
27474557	980	991	Xylan-based	T109	C0062221
27474557	992	1001	hydrogels	T122	C0600484
27474557	1020	1033	biocompatible	T080	C1524057
27474557	1039	1050	NIH3T3 cell	T025	C0007600
27474557	1054	1063	MTT assay	T062	C2986858
27474557	1104	1117	drug carriers	T122	C0013161
27474557	1126	1136	intestinal	T023	C0021853
27474557	1139	1147	targeted	T169	C1521840
27474557	1148	1166	oral drug delivery	T061	C0001563